NO20001962L - Terapeutisk anvendelse av kinolinderivater - Google Patents

Terapeutisk anvendelse av kinolinderivater

Info

Publication number
NO20001962L
NO20001962L NO20001962A NO20001962A NO20001962L NO 20001962 L NO20001962 L NO 20001962L NO 20001962 A NO20001962 A NO 20001962A NO 20001962 A NO20001962 A NO 20001962A NO 20001962 L NO20001962 L NO 20001962L
Authority
NO
Norway
Prior art keywords
therapeutic use
quinoline derivatives
chemical bond
hydrogen
vicinal
Prior art date
Application number
NO20001962A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001962D0 (no
Inventor
Zaid Jayyosi
Gerard M Mcgeehan
Michael F Kelley
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20001962D0 publication Critical patent/NO20001962D0/no
Publication of NO20001962L publication Critical patent/NO20001962L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20001962A 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater NO20001962L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1998/021947 WO1999020275A1 (fr) 1997-10-17 1998-10-16 Utilisations therapeutiques de derives de quinoline

Publications (2)

Publication Number Publication Date
NO20001962D0 NO20001962D0 (no) 2000-04-14
NO20001962L true NO20001962L (no) 2000-06-16

Family

ID=26742119

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Country Status (17)

Country Link
US (1) US6376512B1 (fr)
EP (1) EP1030665A4 (fr)
JP (1) JP2001520193A (fr)
KR (1) KR20010024533A (fr)
CN (1) CN1302206A (fr)
AP (1) AP2000001786A0 (fr)
AU (1) AU9696198A (fr)
BG (1) BG104432A (fr)
BR (1) BR9814087A (fr)
CA (1) CA2306825A1 (fr)
EA (1) EA200000427A1 (fr)
HU (1) HUP0101022A1 (fr)
IL (1) IL135673A0 (fr)
NO (2) NO20001962L (fr)
OA (1) OA11371A (fr)
PL (1) PL344977A1 (fr)
WO (1) WO1999020275A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
ES2261202T3 (es) * 1999-04-28 2006-11-16 Sanofi-Aventis Deutschland Gmbh Derivados de acido de triarilo como ligandos para el receptor ppar.
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CA2382966A1 (fr) 1999-08-27 2001-03-08 Eli Lilly And Company Derives de biaryl-oxa(thia)zole et leur utilisation en tant que modulateurs de ppar
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1357115B1 (fr) 2000-12-28 2009-06-17 Takeda Pharmaceutical Company Limited Derives d'acide alcanoique, procede de production et utilisation correspondants
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
NZ530051A (en) 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
EP1452521A4 (fr) * 2001-08-17 2007-03-14 Eisai R&D Man Co Ltd Compose cyclique et agoniste du recepteur ppar
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
JP4531049B2 (ja) * 2003-09-17 2010-08-25 ノバルティス アーゲー 有機化合物
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (fr) 2004-05-05 2005-11-10 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
EP1979311B1 (fr) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Acides phénoxyacétiques en tant qu'activateurs ppar delta
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
CA2663121C (fr) 2006-09-08 2016-01-19 Rhode Island Hospital Traitement, prevention et elimination d'une maladie cerebrale d'origine alcoolique
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
ES2561039T3 (es) 2008-04-30 2016-02-24 Wellstat Therapeutics Corporation Compuestos tetrazol para reducir el ácido úrico
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
US9078902B2 (en) 2009-06-09 2015-07-14 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
WO2010144586A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog
EP2590951B1 (fr) 2010-07-09 2015-01-07 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
CA2804351A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2015157187A1 (fr) * 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Modulateurs allostériques positifs (pam) du récepteur métabotropique du glutamate et leurs utilisations
CN116323560A (zh) * 2020-08-04 2023-06-23 精密生物治疗有限责任公司 作为胆汁酸受体和白三烯半胱氨酰受体的选择性和/或双重调节剂的喹啉化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
PT731791E (pt) * 1993-11-29 2000-11-30 Merrell Pharma Inc Novos derivados de benzeno-sulfonil-imina como inibidores da accao da il-1.
EP0709377B1 (fr) * 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Procédé pour la préparation de composés d'acide benzoique
EP0871439B1 (fr) * 1996-01-02 2004-03-31 Aventis Pharmaceuticals Inc. Composes d'acide (aryle, heteroaryle, arylmethyle ou heteroarylmethyle) hydroxamique substitues

Also Published As

Publication number Publication date
OA11371A (en) 2004-01-28
PL344977A1 (en) 2001-11-19
BG104432A (bg) 2000-12-29
WO1999020275A1 (fr) 1999-04-29
EP1030665A1 (fr) 2000-08-30
US6376512B1 (en) 2002-04-23
BR9814087A (pt) 2000-10-03
CA2306825A1 (fr) 1999-04-29
AU9696198A (en) 1999-05-10
CN1302206A (zh) 2001-07-04
EP1030665A4 (fr) 2002-11-27
NO20003107D0 (no) 2000-06-16
NO20001962D0 (no) 2000-04-14
NO20003107L (no) 2000-07-26
KR20010024533A (ko) 2001-03-26
AP2000001786A0 (en) 2000-04-16
HUP0101022A1 (hu) 2001-10-28
IL135673A0 (en) 2001-05-20
EA200000427A1 (ru) 2001-02-26
JP2001520193A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20001962L (no) Terapeutisk anvendelse av kinolinderivater
ATE169915T1 (de) Pyrimidindionderivate, deren herstellung und verwendung
ES2065880T3 (es) Proteina quimicamente modificada y obtencion de la misma.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
HU913082D0 (en) Method for producing compounds having fibrinogene receptor antagonistic effect and therapeutical preparatives containing such compounds
EP0303465A3 (fr) Dérivés de phénéthanolamine
ES2108120T3 (es) Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
TR200100694T2 (tr) Opioid alıcı aktivitesine sahip 4,4-Biarilpiperidin türevleri
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
TR200101978T2 (tr) 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri.
FI852806A0 (fi) 2-substituerade -1,3-propylidendifosfonatderivat och deras framstaellning.
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
FI851261L (fi) Substituerade bensopyraner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DE69409796D1 (de) Neue verwendung bis-heterocyclische verbindungen und dessen zusammensetzungen
DE69528103D1 (de) Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz
DK0845984T3 (da) Anvendelse af aminoadamantan-forbindelser som immunregulatorer
IL125926A0 (en) Compounds related to the amidinium family pharmaceutical compositions containing them and uses thereof
DK167384D0 (da) Penemer,farmaceutiske praeparater indeholdende disse,samt fremgangsmaader til fremstilling deraf
CY2225B1 (en) Organic compounds
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
ATE247955T1 (de) Selenophen-antitumormittel
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
NO994764L (no) Nye pyridinderivater og farmasöytiske preparater inneholdende disse
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus
DK360388D0 (da) Laegemiddel til behandling af hjerteinsufficiens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application